ICCM Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

901.00K

+2.97%

-0.040

-50%

2.15M

+196.97%

-0.040

-33.33%

2.95M

+462.48%

-0.030

-50%

Estimates Revision

The market is revising No Change the revenue expectations for IceCure Medical Ltd (ICCM) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -26.34%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-26.34%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast ICCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICCM is 2.75 USD with a low forecast of 2.50 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

2.50

Averages

2.75

High

3.00

Current: 0.000

Low

2.50

Averages

2.75

High

3.00

H.C. Wainwright

Yi Chen

Buy

downgrade

2025-08-15

Reason

H.C. Wainwright

Yi Chen

Price Target

2025-08-15

downgrade

Buy

Reason

H.C. Wainwright analyst Yi Chen lowered the firm's price target on IceCure Medical to $2 from $2.50 and keeps a Buy rating on the shares post the Q2 report. The firm's projected shares outstanding in 12 months increased meaningfully as a result of IceCure's recent rights offering.

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

$2.5

2025-03-28

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$2.5

2025-03-28

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Icecure Medical Ltd (ICCM.O) is -5.73, compared to its 5-year average forward P/E of -5.42. For a more detailed relative valuation and DCF analysis to assess Icecure Medical Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.42

Current PE

-5.73

Overvalued PE

1.63

Undervalued PE

-12.48

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

14.78

Current PS

4.00

Overvalued PS

30.00

Undervalued PS

-0.44

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ICCM News & Events

Events Timeline

No data

News

9.5

2025-12-17PRnewswire

IceCure Medical Expects Record Q4 Sales Surge in North America Following FDA Approval

3.5

2025-12-10PRnewswire

IceCure Medical Presents Four Studies Supporting Broader Adoption of ProSense® at RSNA 2025

3.5

2025-12-05PRnewswire

IceCure Secures China Patent for Cryogen Flow Control, Enhancing Cryoablation Technology

People Also Watch

Frequently Asked Questions

What is Icecure Medical Ltd (ICCM) stock price today?

The current price of ICCM is 0.7103 USD — it has increased 1.14 % in the last trading day.

What is Icecure Medical Ltd (ICCM)'s business?

Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.

What is the price predicton of ICCM Stock?

What is Icecure Medical Ltd (ICCM)'s revenue for the last quarter?

Icecure Medical Ltd revenue for the last quarter amounts to 850.00K USD, increased 28.40 % YoY.

What is Icecure Medical Ltd (ICCM)'s earnings per share (EPS) for the last quarter?

Icecure Medical Ltd. EPS for the last quarter amounts to -0.06 USD, decreased -25.00 % YoY.

What changes have occurred in the market's expectations for Icecure Medical Ltd (ICCM)'s fundamentals?

How many employees does Icecure Medical Ltd (ICCM). have?

Icecure Medical Ltd (ICCM) has 64 emplpoyees as of January 10 2026.

What is Icecure Medical Ltd (ICCM) market cap?

Today ICCM has the market capitalization of 48.98M USD.